Effects of adjunctive corticosteroids therapy in Non-HIV Pneumocystis jirovecii pneumonia: a real-world multicenter cohort study Authors: Ting-Wei Kao, Sheng-Yuan Ruan, Chia-Jung Liu, You-Yi Chen, Yu-Tsung Huang, Chong-Jen Yu, Jung-Yien Chien, Kuei-Pin Chun, Kuei-Pin Chun, Wei-Lun Liu Published: 2025 ABSTRACT Pneumocystis jirovecii pneumonia (PJP) constitutes a significant clinical burden even in patients without HIV infection, but the role of corticosteroids in such population remained controversial. The multicenter retrospective study aimed to evaluate the impact of adjunctive corticosteroids on outcomes in non-HIV patients with PJP. The primary outcome was all-cause mortality at 60 days. Among 334 enrolled subjects, 251 (75.1%) received adjunctive corticosteroids. Kaplan-Meier analysis showed higher 60-days mortality rate in patients with adjunctive corticosteroids (log-rank P < 0.001). However, corticosteroid-treated patients showed more shock (43.0% vs. 25.3%; P = 0.002) and worse PaO2/FiO2 (183.3 vs. 290.3; P < 0.001). By multivariable and 1:1 propensity score matching analysis, adjunctive corticosteroid therapy was not associated with higher mortality (log-rank P = 0.13). Subgroup analyses were conducted to explore potential effect modifiers. Among the subgroup of patients without shock, we found adjunctive corticosteroids were associated with higher mortality (odds ratio 2.72, 95% confidence interval 1.11–6.66; P = 0.03). The observed association between adjunctive corticosteroids and higher 60-day mortality in non-HIV PJP might primarily relate to underlying indications for corticosteroid use rather than direct therapeutic effects. Adjunctive steroid used in patients with low disease severity should therefore be reconsidered. Introduction Pneumocystis jirovecii pneumonia (PJP) is a fulminant pulmonary disease entity that mostly presents as an opportunistic infection in immunocompromised individuals and frequently leads to acute respiratory distress syndrome (ARDS), mechanical ventilation, intensive care unit admission, and death. Historically, the prevalence of PJP has been especially high in patients with human immunodeficiency virus (HIV) infection, with a mortality rate of 17%1. In the last two decades, a growing population of patients administered immunosuppressants, with hematological disorders, and with solid cancers have also been predisposed to PJP2. These patients sustain higher rates of respiratory failure and mortality than those with HIV3. The management of PJP relies on prompt initiation of curative antibiotic treatment following diagnosis4. In addition to direct fungal injury, PJP causes hazardous inflammation by interacting with the airway epithelium, immune cells, and cytokines5. Increased neutrophil counts in bronchoalveolar lavage fluid are associated with poor oxygenation and survival6. However, the role of adjunctive corticosteroids has been debated. The quantity of Pneumocystis in respiratory samples had been proposed to be substantially higher in individuals with HIV than in non-HIV immunocompromised patients, and such difference impacted not only the diagnostic thresholds but also the indication to initiate adjunctive therapies such as corticosteroids7. Previous trials have proposed the beneficial effects of adjunctive corticosteroids in patients with HIV, but these studies were conducted decades ago with relatively small sample sizes8. In non-HIV patients, a retrospective cohort study suggested that individuals administered early corticosteroids presented similar rates of mortality and respiratory failure9. However, in a meta-analysis, the overall effects of corticosteroids appeared to be hazardous. Nevertheless, stratified analysis suggested that adjunctive corticosteroids improved all-cause mortality only in the presence of respiratory failure or hypoxemia10. Divergent host factors and disease severities have highlighted a long-term unmet clinical need to determine steroid use. Therefore, this study was conducted to evaluate the effect of adjunctive corticosteroids in non-HIV patients with PJP in a large multicenter cohort and to further explore its role in distinct patient subpopulations. Patient and methods Study design and population A multi-center retrospective cohort study was conducted during November 10th 2016, and December 20th 2023 in National Taiwan University Hospital and three affiliated branches in Taiwan. We considered the inclusion of consecutive patients who (1) had probable PJP based on EORTC/MSGERC definition11 (presence of appropriate host factors, clinical, and radiologic criteria, in addition to amplification of Pneumocystis jirovecii deoxyribonucleic acid by quantitative real-time polymerase chain reaction in respiratory specimen), (2) deemed pathogenic instead of colonization and thus received anti-Pneumocystis jirovecii agent (trimethoprim/sulfamethoxazole or anidulafungin) at a therapeutic dose, and (3) were followed till death or for 60 days regardless remaining hospitalized or discharged, whichever occurred first. Exclusion criteria were patients with HIV, pediatric patients aged less than 18 years, and individuals who were initially treated with anidulafungin as the primary agent for Pneumocystis jirovecii treatment. Each patient was included only once, even if recurrent Pneumocystis jirovecii infections were present. Ethical issues The study was approved by the National Taiwan University Hospital Research Ethics Committee (202002106RIND). The study was conducted in accordance with the Declaration of Helsinki, and the need for informed consent was waived by the institutional review board of National Taiwan University Hospital Research Ethics Committee owing to the retrospective nature of the study. Data extraction Patient-level characteristics were obtained from a linked population-based administrative electronic medical records system. We extracted the demographic parameters (age, sex, body height, body weight, body mass index), disease severity and corresponding treatment (initial cyclic threshold of Pneumocystis jirovecii polymerase chain reaction, hospital length of stay, shock, arterial oxygen tension/inspiratory oxygen fraction ratio (PaO2/FiO2), respiratory failure, mechanical ventilation, intensive care unit admission, in-hospital mortality, trimethoprim dose per body weight), chronic underlying conditions (hypertension, diabetes mellitus, stroke, heart failure, chronic kidney disease, dialysis, cirrhosis, asthma, chronic obstructive lung disease (COPD), intestinal lung disease, hematological malignancy, peripheral blood stem cell transplantation, solid cancer, solid organ transplantation, autoimmune disease, HIV), and selected laboratory data (absolute leukocyte count, hemoglobin, platelet, C-reactive protein, lactate dehydrogenase) based on the planning case record form. The type, dose, and time of initiation of adjunctive steroid as well as exposure of steroid with its type and dosage prior to PJP diagnosis were documented. The average steroid dosage was recorded as the methylprednisolone equivalent after conversion of anti-inflammatory effects. PJP is diagnosed based on clinical (fever, cough, dyspnea, or hypoxia), imaging (diffuse interstitial or alveolar pattern bilaterally on chest plain film; nodular or patchy ground-glass opacities on computed tomography)12, and microbiological criteria (positive automated real-time quantitative polymerase chain reaction assay (Becton Dickinson, Franklin Lakes, New Jersey, USA) of sputum, endotracheal aspirates, or bronchoalveolar lavage samples for Pneumocystis jirovecii detection)13,14. The qualitative polymerase chain reaction for Pneumocystis jirovecii was available throughout the study period. Enrolled patients were defined as steroid users if any kind of steroid had been introduced adjunctively after the initiation of Pneumocystis jirovecii treatment, regardless of baseline steroid administration. Shock is defined pragmatically as systemic arterial hypotension (mean arterial pressure < 70 mmHg, systolic blood pressure < 90 mmHg, or use of vasopressors/inotropic agents necessary for circulatory support). Respiratory failure was defined as tachypnea (respiratory rate exceeding 30 breaths per minute) and pronounced hypoxemia (PaO2/FiO2 ≤ 200)15. SpO2/FiO2 was recorded as a surrogate of PaO2/FiO2 based on the established formula if PaO2 is not available16. The primary outcome was all-cause mortality at 60 days, which has been validated as a widely used timeframe in previous randomized controlled trials on steroid use in patients with severe community-acquired pneumonia17 and ARDS18. As other clinical endpoints, including respiratory failure and shock, were parameters for propensity score matching (PSM), they were not included as study outcomes. Statistical analysis Statistical analyses were conducted using R software, version 4.3.3 (R Core Team, 2024). Continuous variables are expressed as means with standard deviations, whereas categorical variables are expressed as absolute numbers with percentages. Variables with a P value < 0.15 in the univariable logistic or Cox regression analysis were included in the multivariable model using backward conditional selection and expressed as odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI). Subgroup analyses were conducted based on prespecified baseline conditions, which have been reported to alter the prognosis of PJP. The cohort was stratified according to age, sex, shock, respiratory failure, fungal load, lymphocyte count, solid cancers, and autoimmune diseases. Cutoffs of lymphocyte count and cycle threshold of Pneumocystis jirovecii polymerase chain reaction were determined by respective median. Relative risk (RR) with corresponding 95% CI were reported. The Kaplan-Meier method was used to illustrate the accumulation of mortality events to assess the effect of adjunctive corticosteroids, and the performance of subgroups stratified by PaO2/FiO2 and presence of shock were assessed. Besides, propensity score matching was applied to minimize confounding by indication when unbiased causal therapeutic effects were determined. The propensity score has been well established for quantifying the probability of a certain treatment being assigned according to the observed baseline characteristics19. A total of 23 potential confounders were used a priori to estimate the propensity scores (Supplementary Table S1). Calibre was designated as 0.2 standard deviation of the logit propensity score for 1:1 matching20. The standardized mean differences before and after matching were depicted by Love plot. Inverse probability of treatment weighting was performed as a sensitivity analysis to the primary analysis method21. All comparisons with two-tailed P values less than 0.05 indicated statistical significance. Results We identified 430 participants who met the inclusion criteria during the study period. After excluding 67 patients (50 with HIV, 15 pediatrics, and two treated aside from trimethoprim), a total of 334 individuals were included. The baseline demographic and clinical characteristics are listed in Table 1. The mean age of the cohort was 62.9 ± 15.3 years, with 204 (61.1%) males. Among the included population, 251 (75.1%) patients received adjunctive corticosteroids during PJP treatment, and all steroids were introduced within 24 h of therapeutic initiation. Trimethoprim was administered at a significantly higher dose in steroid users (12.3 vs. 10.8 mg/kg/d; P < 0.001). The burden of fungal load, as quantified by the initial Ct value, was equivalent between the two groups (26.6 vs. 26.8; P = 0.65). Malignancies (62.0%) and autoimmune diseases (20.1%) were the most common comorbidities among the cohort. The rate of shock was significantly higher in the steroid group compared to the non-steroid group (43.0% vs. 25.3%; P = 0.002), while PaO2/FiO2 was remarkably lower (183.3 vs. 290.3; P < 0.001). Table 1Baseline demographics.All(n = 334)With adjunctive steroids (n = 251)Without adjunctive steroids (n = 83) P Age (year)62.9 ± 15.362.8 ± 15.063.2 ± 16.20.84Sex (male)204 (61.1%)154 (61.4%)50 (60.2%)0.85Body height (cm)162.3 ± 8.6162.3 ± 8.0162.5 ± 10.30.85Body weight (kg)59.6 ± 11.659.6 ± 11.659.6 ± 11.71.00Body mass index (kg/m2)22.6 ± 3.922.6 ± 3.922.6 ± 3.81.00Initial Ct value of PCR26.7 ± 3.526.6 ± 3.426.8 ± 3.90.65Trimethoprim dose (g/kg/d)11.9 ± 3.512.3 ± 3.510.8 ± 3.4 < 0.001 Hypertension98 (29.3%)77 (30.7%)21 (25.3%)0.35Diabetes mellitus71 (21.3%)56 (22.3%)15 (18.1%)0.42Stroke21 (6.3%)16 (6.4%)5 (6.0%)0.90Heart failure27 (8.1%)20 (8.0%)7 (8.4%)0.91Chronic kidney disease58 (17.4%)45 (17.9%)13 (15.7%)0.65Dialysis24 (7.2%)19 (7.6%)5 (6.0%)0.63Cirrhosis5 (1.5%)4 (1.6%)1 (1.2%)0.80Asthma7 (2.1%)5 (2.0%)2 (2.4%)0.83Chronic obstructive lung disease33 (9.9%)25 (10.0%)8 (9.6%)0.92Interstitial lung disease14 (4.2%)13 (5.2%)1 (1.2%)0.12Malignancy207 (62.0%)156 (62.2%)51 (61.4%)0.90PBSCT22 (6.6%)13 (5.2%)9 (10.8%)0.08Autoimmune disease67 (20.1%)61 (24.3%)6 (7.2%) 0.008 Shock129 (38.6%)108 (43.0%)21 (25.3%) 0.002 PaO2/FiO2209.9 ± 138.0183.28 ± 123.1290.3 ± 149.6 < 0.001 Ct: cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio.Significant values are in bold. Table 1Baseline demographics.All(n = 334)With adjunctive steroids (n = 251)Without adjunctive steroids (n = 83) P Age (year)62.9 ± 15.362.8 ± 15.063.2 ± 16.20.84Sex (male)204 (61.1%)154 (61.4%)50 (60.2%)0.85Body height (cm)162.3 ± 8.6162.3 ± 8.0162.5 ± 10.30.85Body weight (kg)59.6 ± 11.659.6 ± 11.659.6 ± 11.71.00Body mass index (kg/m2)22.6 ± 3.922.6 ± 3.922.6 ± 3.81.00Initial Ct value of PCR26.7 ± 3.526.6 ± 3.426.8 ± 3.90.65Trimethoprim dose (g/kg/d)11.9 ± 3.512.3 ± 3.510.8 ± 3.4 < 0.001 Hypertension98 (29.3%)77 (30.7%)21 (25.3%)0.35Diabetes mellitus71 (21.3%)56 (22.3%)15 (18.1%)0.42Stroke21 (6.3%)16 (6.4%)5 (6.0%)0.90Heart failure27 (8.1%)20 (8.0%)7 (8.4%)0.91Chronic kidney disease58 (17.4%)45 (17.9%)13 (15.7%)0.65Dialysis24 (7.2%)19 (7.6%)5 (6.0%)0.63Cirrhosis5 (1.5%)4 (1.6%)1 (1.2%)0.80Asthma7 (2.1%)5 (2.0%)2 (2.4%)0.83Chronic obstructive lung disease33 (9.9%)25 (10.0%)8 (9.6%)0.92Interstitial lung disease14 (4.2%)13 (5.2%)1 (1.2%)0.12Malignancy207 (62.0%)156 (62.2%)51 (61.4%)0.90PBSCT22 (6.6%)13 (5.2%)9 (10.8%)0.08Autoimmune disease67 (20.1%)61 (24.3%)6 (7.2%) 0.008 Shock129 (38.6%)108 (43.0%)21 (25.3%) 0.002 PaO2/FiO2209.9 ± 138.0183.28 ± 123.1290.3 ± 149.6 < 0.001 Ct: cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio.Significant values are in bold. Baseline demographics. Ct: cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio. Significant values are in bold. The primary outcome occurred in 135 patients (40.4% of the study population), with 117 and 18 events occurring in the adjunctive steroid and non-steroid groups, respectively. Kaplan-Meier curves indicated a significantly higher 60-day mortality in adjunctive steroid users by crude analysis (log-rank P < 0.001) (Fig. 1A). The even worse prognosis was present in patients administered with higher dose of adjunctive steroid (Supplementary Figure S1). However, in multivariable analysis by either logistic regression or Cox survival model, both adjunctive corticosteroid and prior steroid exposure were not an independent risk factor associated with 60-day mortality in the overall population (Table 2, Supplementary Table S2). To validate, we further performed a 1:1 propensity score matching (PSM) analysis. Total 128 patients retained in each arm (Supplementary Figure S2). The distributions of propensity scores and Love plot were presented (Supplementary Figure S3, Supplementary Figure S4). No significant differences were observed in baseline characteristics after matching (Supplementary Table S3). Kaplan-Meier curves showed no significant difference in mortality between groups (log-rank P = 0.13; Supplementary Figure S5). Sensitivity analysis using inverse probability of treatment weighting yielded consistent results (risk difference, 6.2%, 95% CI, -10% − 22.5%). Subgroup analyses after PSM defined by stratification factors revealed no significant effect modifiers (Supplementary Figure S6). The impact of adjunctive steroids did not reach statistical significance among all subgroups. Fig. 1Kaplan-Meier curve of 60-day all-cause mortality in (A) all patients (B) PaO2/FiO2 ≤ 100 (C) 100 < PaO2/FiO2 ≤ 200 (D) PaO2/FiO2 > 200 (E) without shock (F) with shock. PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio. Kaplan-Meier curve of 60-day all-cause mortality in (A) all patients (B) PaO2/FiO2 ≤ 100 (C) 100 < PaO2/FiO2 ≤ 200 (D) PaO2/FiO2 > 200 (E) without shock (F) with shock. PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio. Table 2Univariable and multivariable analysis of 60-day all-cause mortality.All subjectsSubjects without shockUnivariableMultivariableUnivariableMultivariableOR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P Adjunctive steroid3.15 (1.77–5.62) < 0.001 4.22 (1.87–9.53) 0.001 2.72 (1.11–6.66) 0.03 Prior steroid exposure1.43 (0.92–2.22) 0.12 2.32 (1.23–4.35) 0.009 Age (year)1.01 (1.00-1.03) 0.09 1.02 (1.00-1.04) 0.09 Sex (male)1.03 (0.66–1.61)0.901.20 (0.65–2.22)0.56Body mass index (kg/m2)0.97 (0.92–1.03)0.380.95 (0.88–1.03)0.20Initial Ct value of PCR0.97 (0.91–1.03)0.270.98 (0.90–1.06)0.57Trimethoprim dose (g//BW/d)1.08 (1.02–1.16) 0.02 1.08 (0.98–1.18) 0.11 Hypertension0.85 (0.53–1.39)0.520.90 (0.47–1.71)0.75Diabetes mellitus1.19 (0.70–2.01)0.531.59 (0.78–3.25)0.20Stroke0.72 (0.28–1.84)0.501.14 (0.33–3.92)0.84Heart failure1.02 (0.46–2.26)0.970.96 (0.35–2.63)0.94Chronic kidney disease0.88 (0.49–1.58)0.670.88 (0.40–1.97)0.76Dialysis1.52 (0.66–3.49)0.323.78 (1.28–11.1) 0.02 Cirrhosis2.24 (0.37–13.6)0.382.27 (0.14–36.9)0.56Chronic obstructive pulmonary disease0.71 (0.33–1.53)0.380.47 (0.15–1.44)0.19Malignancy1.65 (1.04–2.62) 0.03 1.85 (1.12–3.08) 0.02 1.94 (1.02–3.67) 0.04 2.10 (1.03–4.29) 0.04 PBSCT0.53 (0.20–1.40)0.200.74 (0.19–2.83)0.66Autoimmune disease1.16 (0.67–1.99)0.591.33 (0.65–2.72)0.43ALC0.93 (0.76–1.15)0.511.01 (0.81–1.26)0.96PaO2/FiO20.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 Shock2.85 (1.80–4.50) < 0.001 1.77 (1.07–2.92) 0.03 OR, odds ratio; CI, confidence interval; Ct, cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; ALC, absolute lymphocyte count; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio.Significant values are in bold. Table 2Univariable and multivariable analysis of 60-day all-cause mortality.All subjectsSubjects without shockUnivariableMultivariableUnivariableMultivariableOR (95% CI) P OR (95% CI) P OR (95% CI) P OR (95% CI) P Adjunctive steroid3.15 (1.77–5.62) < 0.001 4.22 (1.87–9.53) 0.001 2.72 (1.11–6.66) 0.03 Prior steroid exposure1.43 (0.92–2.22) 0.12 2.32 (1.23–4.35) 0.009 Age (year)1.01 (1.00-1.03) 0.09 1.02 (1.00-1.04) 0.09 Sex (male)1.03 (0.66–1.61)0.901.20 (0.65–2.22)0.56Body mass index (kg/m2)0.97 (0.92–1.03)0.380.95 (0.88–1.03)0.20Initial Ct value of PCR0.97 (0.91–1.03)0.270.98 (0.90–1.06)0.57Trimethoprim dose (g//BW/d)1.08 (1.02–1.16) 0.02 1.08 (0.98–1.18) 0.11 Hypertension0.85 (0.53–1.39)0.520.90 (0.47–1.71)0.75Diabetes mellitus1.19 (0.70–2.01)0.531.59 (0.78–3.25)0.20Stroke0.72 (0.28–1.84)0.501.14 (0.33–3.92)0.84Heart failure1.02 (0.46–2.26)0.970.96 (0.35–2.63)0.94Chronic kidney disease0.88 (0.49–1.58)0.670.88 (0.40–1.97)0.76Dialysis1.52 (0.66–3.49)0.323.78 (1.28–11.1) 0.02 Cirrhosis2.24 (0.37–13.6)0.382.27 (0.14–36.9)0.56Chronic obstructive pulmonary disease0.71 (0.33–1.53)0.380.47 (0.15–1.44)0.19Malignancy1.65 (1.04–2.62) 0.03 1.85 (1.12–3.08) 0.02 1.94 (1.02–3.67) 0.04 2.10 (1.03–4.29) 0.04 PBSCT0.53 (0.20–1.40)0.200.74 (0.19–2.83)0.66Autoimmune disease1.16 (0.67–1.99)0.591.33 (0.65–2.72)0.43ALC0.93 (0.76–1.15)0.511.01 (0.81–1.26)0.96PaO2/FiO20.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 0.99 (0.99-1.00) < 0.001 Shock2.85 (1.80–4.50) < 0.001 1.77 (1.07–2.92) 0.03 OR, odds ratio; CI, confidence interval; Ct, cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; ALC, absolute lymphocyte count; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio.Significant values are in bold. Univariable and multivariable analysis of 60-day all-cause mortality. OR, odds ratio; CI, confidence interval; Ct, cycle threshold; PCR, polymerase chain reaction; PBSCT, peripheral blood stem cell transplantation; ALC, absolute lymphocyte count; PaO2/FiO2, arterial oxygen tension/inspiratory oxygen fraction ratio. Significant values are in bold. Regarding survival trajectory in subgroups, no statistically significant differences were observed when stratified by PaO2/FiO2 with cutoffs at 100 and 200. However, there was a signal suggesting worse outcomes in the 107 patients with adjunctive corticosteroid use when PaO2/FiO2 was between 100 and 200 (log-rank P = 0.07) (Fig. 1B-D). Patients with shock showed comparable results between groups (log-rank P = 0.27), but significantly poorer outcomes were demonstrated in the steroid group among patients without shock (log-rank P < 0.001) (Fig. 1E-F). Detailed baseline parameters by adjunctive corticosteroid use in subjects without shock are summarized (Supplementary Table S4). Baseline characteristics between patients with and without adjunctive steroid were comparable except that individuals receiving adjunctive corticosteroids had a higher prevalence of autoimmune diseases (25.9% vs. 8.1%; P = 0.004) and received higher doses of trimethoprim (12.0 vs. 10.3 mg/kg/d; P < 0.001). Furthermore, multivariable analysis revealed that in individuals without shock, adjunctive steroids (OR 2.72, 95% CI 1.11–6.66; P = 0.03), in conjunction with malignancy (OR 2.10, 95% CI 1.03–4.29; P = 0.04), and lower PaO2/FiO2 (OR 0.99, 95% CI 0.99-1.00; P < 0.001) were independently associated with increased risk of 60-day mortality (Table 2). Discussion This study provided a detailed analysis of the clinical characteristics of non-HIV patients with PJP and evaluated the effects of adjunctive corticosteroids in this population. The principal findings were as follows: (1) steroid exposure was associated with worse outcome among non-HIV individuals in crude analysis; (2) the unfavorable outcomes may not be directly attributable to adjunctive corticosteroids, but rather to the underlying indications necessitating their use; and (3) adjunctive corticosteroid was associated with unfavorable 60-day survival rates in hemodynamically stable patients and potentially a preliminary trend toward worse prognosis in patients with moderate hypoxemia by exploratory analysis. A recent observational study highlighted the potential association between adjunctive corticosteroid use and increased mortality in PJP22. Kamel et al. included a population with more severe disease states, in which 64.6% of the patients received adjunctive corticosteroids, a proportion comparable to that in our cohort. Notably, more than half of these patients were prescribed corticosteroids for indications beyond PJP, e.g. inflammatory diseases, ARDS, septic shock, and adrenal insufficiency23. Such a scenario reflects a real-world clinical setting, as seen in our cohort, where patients frequently experience hemodynamic or respiratory instability and often have comorbid conditions that contribute to immunosuppression. After adjusting for these confounding factors, the differences in 60-day mortality between the groups with and without corticosteroid use were no longer significant, suggesting that the observed disparities in outcomes were largely confounded by the indications for corticosteroid administration. The survival curves of patients with and without adjunctive corticosteroid therapy in our study were consistent with those of previous reports3. During the initial two weeks of PJP treatment, patients receiving corticosteroids showed a trend toward decreased mortality. This early survival benefit may be attributed to the anti-inflammatory effects of corticosteroids, which mitigate acute inflammatory responses during the initial disease phase. However, the survival benefits diminish over time, and the subsequent increase in mortality could be secondary to the progression of underlying conditions necessitating corticosteroids or the adverse effects associated with prolonged corticosteroid use. Notably, the study proposed notable heterogeneous therapeutic effects in different subgroups, and adjunctive steroid was especially associated with a trend of worse outcome in selected population. Steroid users were demonstrated with significantly worse hemodynamics and oxygenation status, possibly resulted in the significantly higher dose of trimethoprim. The efficacy of adjunctive corticosteroids appears to depend on the severity of the respiratory decompensation. Recent ARDS treatment guidelines26 conditionally recommend corticosteroids, although earlier recommendations restricted their use to moderate-to-severe ARDS, defined as a PaO2/FiO2 ratio below 20025. Our findings suggested that the negative effects of adjunctive corticosteroids were more pronounced in patients without respiratory failure. This aligns with previous literature indicating that corticosteroids should only be used for PJP with hypoxemia, even in HIV-infected populations. Mild respiratory compromise alone does not justify the use of corticosteroids. Similarly, corticosteroid administration in patients with autoimmune diseases is often driven by underlying conditions rather than PJP26. However, it remains unclear whether these discrepant effects are due to underlying comorbidities or different responses of Pneumocystis jirovecii pathogens. These findings underscore the need for future trials evaluating whether adjunctive corticosteroid therapy should be guided by specific clinical indicators and/or inflammatory biomarkers. Notably, in selected population such as those without respiratory failure or without shock, the introduction of adjunctive corticosteroid should be prudent. The major strength of this study lies in its relatively large sample size compared with previous cohorts, allowing for a more robust investigation of this distinct clinical entity. However, this study has some limitations. First, the retrospective design inherently limited causal inference between adjunctive corticosteroid therapy and mortality outcomes. While propensity score matching reduced confounding, unmeasured variable including clinical indications driving treatment decisions may introduce residual bias. Besides, some without PaO2/FiO2 were surrogated with SpO2/FiO2 to exhibit oxygenation status, and lack of comparisons among different institutions might underestimate variance and overstate statistical significance. Second, our study grouped disease by broad categories owing to sample size constraints, therein masking the heterogeneities among different disease entities. Patients with solid cancers have been associated with the worse survival27, and recent evidence suggests that PJP carries an even higher mortality risk in patients with primary lung cancer than in those with other solid malignancies28. Further investigations into the role of corticosteroids in these subgroups are warranted29. Third, the single ethnicity of this study limited the generalizability of the findings. Further multi-ethnic validation studies are warranted to improve generalizability. Forth, extensive subgroup analyses stratified by numerous parameters were performed to explore possible risk factors, multiple comparisons might raise type 1 error and therefore the interpretation of study findings should be prudent. Finally, even though the adjunctive corticosteroids were all administered shortly after PJP diagnosis and the impacts of the higher verses lower dose were interrogated, the heterogeneities among corticosteroid regimen characteristics might have confounded the observed effects. Conclusion Our study proposed that adjunctive corticosteroids in non-HIV patients with PJP should be used judiciously. Patients with moderate hypoxemia and without shock experienced potentially worse outcomes with adjunctive steroids. We underscored the need for personalized approaches based on specific clinical indicators. Future prospective trials should focus on identifying optimal candidates to improve outcomes. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1